Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
119.00
+5.50 (4.85%)
Apr 24, 2025, 11:00 AM CST
62.79%
Market Cap 9.59B
Revenue (ttm) n/a
Net Income (ttm) -731.66M
Shares Out 82.67M
EPS (ttm) -9.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 98,380
Average Volume 371,765
Open 116.00
Previous Close 113.50
Day's Range 116.00 - 120.00
52-Week Range 70.50 - 180.50
Beta -0.05
RSI 45.43
Earnings Date Apr 23, 2025

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.